BBOT

NASDAQ · Biotechnology

Bridgebio Oncology Therapeut

Small-Cap Stocks Stocks Under $10 Biotech Stocks Healthcare Stocks

$7.89

+0.03 (+0.38%)

As of May 9, 1:41 AM ET ·

Financial Highlights (FY 2025)

Revenue

230.06M

Net Income

46.84M

Gross Margin

48.0%

Profit Margin

20.4%

Rev Growth

-2.3%

D/E Ratio

0.31

Revenue & Net Income

Margin Trends

	FY 2025	FY 2024	FY 2023
Gross Margin	48.0%	48.0%	48.0%
Operating Margin	34.3%	27.5%	32.1%
Profit Margin	20.4%	27.1%	25.9%

Income Statement

	FY 2025	FY 2024	FY 2023
Revenue	230.06M	225.69M	230.96M
Gross Profit	110.51M	108.41M	110.94M
Operating Income	78.94M	62.12M	74.25M
Net Income	46.84M	61.14M	59.73M
Gross Margin	48.0%	48.0%	48.0%
Operating Margin	34.3%	27.5%	32.1%
Profit Margin	20.4%	27.1%	25.9%
Rev Growth	-2.3%	+22.3%	+7.3%

Balance Sheet

	FY 2025	FY 2024	FY 2023
Total Debt	101.48M	78.03M	86.73M
Total Equity	332.52M	285.68M	295.39M
D/E Ratio	0.31	0.27	0.29

Cash Flow

	FY 2025	FY 2024	FY 2023
EBITDA	108.29M	111.55M	110.87M
Free Cash Flow	56.78M	36.61M	55.99M